Back to topic of the German Company Bayer which Developed the technology:
„
It was with the latter that it completed the functional validation of the monoantithing resistance to Bayer's targeted prolactin (PRL) receptors - a drug that effectively promotes the growth of the hair of elderly redmas, and after six months of treatment, the number of hairs in the hair loss area nearly doubled, even in areas that had previously been nearly completely bald, and the effect continued for more than four years after the drug was discontinued - which led Bayer to transfer its development interest in the drug
" hair loss is just one of its indications, and the new target PRLR of HMI-115 antibody selection has many potential developments, such as endometriosis, lymphosarin disease and other autoimmune diseases
Xiao Ruiping revealed that the above indications have completed the development of clinical Phase I
, in addition, it has also developed innovative pipelines in various fields such as diabetic foot (DFU), rheumatoid arthritis (RA), and has been validated by the NHP platform for First-in-Class drugs
On a schedule, HMI-115, which treats lymphatic fibroids, is first expected to be approved for sale in 2024“
(Before corona)
Guide: Xiao Ruiping has been working in the field of translational medicine for many years, and she is also one of the pioneers of translational medicine. In June, Bayer, a multinational drugmaker, announced that it would launch a Bayer
topic.echemi.com
